Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
rhNGF 20 μg/ml
DRUG
2 trials
Sponsors
Dompé Farmaceutici S.p.A
Conditions
Corneal Ulcer
Dry Eye Syndrome
Keratitis
Neurotrophic Keratitis
Phase 1
Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.
Completed
NCT01756456
Dompé Farmaceutici S.p.A
Corneal Ulcer, Keratitis, Neurotrophic Keratitis
Start: 2013-01-31
End: 2016-05-31
Updated: 2024-04-19
Phase 2
A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye
Completed
NCT03982368
Dompé Farmaceutici S.p.A
Dry Eye Syndrome
Start: 2019-06-10
End: 2020-07-15
Updated: 2024-04-19
Related Papers
Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial.
2024-07-17
7 citations
Neurotrophic factors: promising candidates in tissue regeneration
Neural Regeneration Research
2016-01-01
13 citations
Potential New Modes of Treatment of Neurotrophic Keratopathy.
2015-11-01
24 citations
Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial.
2014-06-01
64 citations